Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection? Theocharis KoufakisOmar G. MustafaKalliopi Kotsa Current Opinion 07 July 2021 Pages: 1365 - 1371
Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care Stephan JacobAndrew J. KrentzLars Rydén Therapy in Practice 24 July 2021 Pages: 1373 - 1379
Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations Dimitrios A. VrachatisKonstantinos A. PapathanasiouSpyridon G. Deftereos Review Article 23 July 2021 Pages: 1381 - 1395
Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa Pim AartsKoen DudinkHessel H. van der Zee Review Article Open access 20 July 2021 Pages: 1397 - 1410
Budesonide/Glycopyrronium/Formoterol: A Review in COPD Young-A Heo Adis Drug Evaluation Open access 03 August 2021 Pages: 1411 - 1422
Correction to: Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis Tamara Pérez-JeldresManuel Alvarez-LobosJesús Rivera-Nieves Correction Open access 30 July 2021 Pages: 1451 - 1451
